S100A6 and familial dilated cardiomyopathy: We reported that normalization of PRA levels (equivalent to WT group) in DCM mice treated with aliskiren, in comparison to control DCM mice treated with vehicle (Figure 4b), improved systolic function (EF, p < 0.05; cardiac output, p < 0.01), reduced systemic edema (ECW levels, p < 0.0001), and prolonged life (p < 0.05) [40].